RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
TG Therapeutics Stock

TG Therapeutics Market capitalization 2024

TG Therapeutics Market capitalization

3.39 B USD

Ticker

TGTX

ISIN

US88322Q1085

WKN

A1JXW7

In 2024, TG Therapeutics's market cap stood at 3.39 B USD, a 236.58% increase from the 1.01 B USD market cap in the previous year.

The TG Therapeutics Market capitalization history

YEARMarket Capitalization (undefined USD)
20232.47
20221.07
20215.17
20202.48
20190.61
20180.81
20170.6
20160.36
20150.67
20140.3
20130.13
20120.07
20110.07
20100.01
20090.01
20080.01
20070.03
20060.05
20050.08
20040.04

TG Therapeutics Aktienanalyse

What does TG Therapeutics do?

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market. TG Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring TG Therapeutics's Market Capitalization

TG Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of TG Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

TG Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in TG Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about TG Therapeutics stock

What is the current TG Therapeutics market capitalization?

The current market capitalization of TG Therapeutics is 3.39 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like TG Therapeutics.

How has the market capitalization of TG Therapeutics developed in recent years?

The market capitalization of TG Therapeutics has increased/decreased by 236.58% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of TG Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of TG Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of TG Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does TG Therapeutics pay?

Over the past 12 months, TG Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TG Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of TG Therapeutics?

The current dividend yield of TG Therapeutics is .

When does TG Therapeutics pay dividends?

TG Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TG Therapeutics?

TG Therapeutics paid dividends every year for the past 0 years.

What is the dividend of TG Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TG Therapeutics located?

TG Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von TG Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TG Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did TG Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of TG Therapeutics in the year 2023?

In the year 2023, TG Therapeutics distributed 0 USD as dividends.

In which currency does TG Therapeutics pay out the dividend?

The dividends of TG Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The TG Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von TG Therapeutics

Our stock analysis for TG Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TG Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.